Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Annals of the Rheumatic Diseases is Scopus-indexed (Q1, CiteScore 34.6), WoS SCIE. Published by Elsevier B.V..
Checked against the index lists dated .
ISSN 0003-4967Verify ISSN ↗1468-2060Verify ISSN ↗
Publisher: Elsevier B.V.
Cost to publish: About US$4,870 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Immunology | 5 / 243 | 98th | Q1 |
| Immunology and Allergy | 5 / 234 | 98th | Q1 |
| Rheumatology | 2 / 77 | 98th | Q1 |
| Biochemistry, Genetics and Molecular Biology (all) | 5 / 223 | 97th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1950–present (also 1945–1948), best quartile Q1, CiteScore 34.6.
Annals of the Rheumatic Diseases is Q1 in Immunology (rank 5 of 243), Q1 in Immunology and Allergy (rank 5 of 234) and Q1 in Rheumatology (rank 2 of 77), by CiteScore 2025. It is ranked in 4 subject areas in all.
Annals of the Rheumatic Diseases is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 34.6, which places it in quartile Q1 at the 98th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 7.286, quartile Q1, with an H-index of 315.
The publisher lists an article processing charge of about US$4,870 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Annals of the Rheumatic Diseases is published by Elsevier B.V. Its print ISSN is 0003-4967 and its online ISSN is 1468-2060.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Annals of the Rheumatic Diseases has an h-index of 373 and a 2-year mean of 1.49 citations per paper (OpenAlex). Its Scopus CiteScore is 34.6, quartile Q1. On 2-year citations it ranks #171 of 240 Scopus journals in Immunology.
Annals of the Rheumatic Diseases published 3,396 papers in 2025; its busiest recent year was 2019 with 4,911. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 97 research articles (2026), authors are most often from United States (18.2%), Germany (12.3%) and United Kingdom (9.5%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 18 retracted papers are recorded (0.2 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.